Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Year: 2015
Type: article
Abstract: Meeting abstracts In previously treated patients with metastatic renal cell carcinoma (mRCC), the programmed death-1 (PD-1) inhibitor antibody nivolumab demonstrated objective response rates of 20%–22% and median overall survival (OS) of 18.2– 25.5 months[[1][1]]. An exploratory biomarker
Authors: Mario Sznol, Mayer Fishman, Bernard Escudier, David F McDermott, Harriet Kluger, Walter M Stadler, Jose Perez-Gracia, Douglas G McNeel, Brendan D Curti, Michael R Harrison, Elizabeth R Plimack, Leonard Appleman, Lawrence Fong, Charles G Drake, Tina C Young, Scott D Chasalow, Petra Ross-MacDonald, Jason S Simon, Dana Walker, Toni K Choueiri
Institutions: Yale Cancer Center, Moffitt Cancer Center, Institut Gustave Roussy, Beth Israel Deaconess Medical Center, Yale University, University of Chicago, Clinica Universidad de Navarra, University of Wisconsin–Madison, Providence Portland Medical Center, Duke Medical Center, Fox Chase Cancer Center, University of Pittsburgh Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
Funder: Adaptive Biotechnologies
OpenAlex ID: W2128159174